Guangzhou Wondfo BiotechLtd Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Zhongxiong Peng

Algemeen directeur

CN¥2.2m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	0.03%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	less than a year

Recente managementupdates

Recent updates

CEO

Zhongxiong Peng (50 yo)

no data

Tenure

CN¥2,166,300

Compensatie

Mr. Zhongxiong Peng is General Manager of Guangzhou Wondfo Biotech Co.,Ltd. He was Deputy General Manager of Guangzhou Wondfo Biotech Co.,Ltd and serves as its Director. He was Deputy General Manager of Gu...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Zhongxiong Peng	GM & Director	no data	CN¥2.17m	0.034% CN¥ 4.0m
Yaping Zhao	Deputy General Manager & Non-Independent Director	less than a year	CN¥2.04m	0.034% CN¥ 4.0m
Cui Ling Wu	Chairman of Supervisory Board	no data	geen gegevens	geen gegevens
Ji Hua Wang	Chairman	no data	CN¥1.49m	10.38% CN¥ 1.2b
Xiao Wei He	Non-Employee Supervisor	less than a year	CN¥1.04m	0.073% CN¥ 8.6m
Lijun Kuang	Supervisor	no data	geen gegevens	geen gegevens
Xinhua Ge	Non-Employee Supervisor	less than a year	geen gegevens	geen gegevens
Zhaohui Duan	Independent Director	no data	geen gegevens	0.000030% CN¥ 3.5k
Congdong Li	Independent Director	no data	CN¥80.00k	geen gegevens
Qingmei Song	Supervisor	no data	geen gegevens	geen gegevens
Dali Li	Non-Independent Director	less than a year	geen gegevens	geen gegevens
Ouyang Wenjin	Independent Director	less than a year	geen gegevens	geen gegevens

0.4yrs

Gemiddelde duur

55.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 300482 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.4 jaar), wat duidt op een nieuw bestuur.

Guangzhou Wondfo BiotechLtd Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

High number of new directors

Insufficient new directors

Less than half of directors are independent

Recent updates

High number of new directors

Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.15 in 3Q 2023)

Investor sentiment deteriorates as stock falls 15%

New minor risk - Share price stability

Guangzhou Wondfo Biotech Co.,Ltd to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 18%

Second quarter 2024 earnings released: EPS: CN¥0.29 (vs CN¥0.30 in 2Q 2023)

Guangzhou Wondfo Biotech Co.,Ltd to Report First Half, 2024 Results on Aug 14, 2024

Investor sentiment improves as stock rises 21%

First quarter 2024 earnings released: EPS: CN¥0.49 (vs CN¥0.46 in 1Q 2023)

New minor risk - Shareholder dilution

Guangzhou Wondfo Biotech Co.,Ltd to Report Q1, 2024 Results on Apr 22, 2024

Investor sentiment deteriorates as stock falls 15%

Guangzhou Wondfo Biotech Co.,Ltd to Report Fiscal Year 2023 Results on Apr 22, 2024

Third quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.14 in 3Q 2022)

Guangzhou Wondfo Biotech Co.,Ltd to Report Q3, 2023 Results on Oct 26, 2023

Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.62 in 2Q 2022)

Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) announces an Equity Buyback for CNY 50 million worth of its shares.

Full year 2022 earnings released: EPS: CN¥2.71 (vs CN¥1.43 in FY 2021)

Now 20% undervalued after recent price drop

Now 22% undervalued

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Now 22% undervalued

Insufficient new directors

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.16 in 3Q 2021)

Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) announces an Equity Buyback for CNY 50 million worth of its shares.

Second quarter 2022 earnings released: EPS: CN¥0.62 (vs CN¥0.90 in 2Q 2021)

Guangzhou Wondfo Biotech Co.,Ltd announced that it expects to receive CNY 1 billion in funding

Guangzhou Wondfo Biotech Co.,Ltd Announces Cash Dividend, Payable on 14 June 2022

Guangzhou Wondfo Biotech Co.,Ltd Approves Cash Dividend for the Year 2021

First quarter 2022 earnings released: EPS: CN¥2.05 (vs CN¥0.35 in 1Q 2021)

Less than half of directors are independent

Guangzhou Wondfo Biotech Co.,Ltd. Announces Profit Distribution Proposal for 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.27 in 3Q 2020)

Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) announces an Equity Buyback for CNY 80 million worth of its shares.

Second quarter 2021 earnings released: EPS CN¥0.90 (vs CN¥0.79 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Guangzhou Wondfo Biotech Co.,Ltd Announces 2020 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 26 May 2021

First quarter 2021 earnings released: EPS CN¥0.46 (vs CN¥0.29 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.87 (vs CN¥1.14 in FY 2019)

Guangzhou Wondfo Biotech Co.,Ltd to Report Fiscal Year 2020 Results on Mar 31, 2021

Wondfo Rams Up Neutralizing Antibody, Antigen and PCR Tests to Address the Evolving Demands for COVID-19 Testing Globally

New 90-day high: CN¥95.02

New 90-day high: CN¥90.79

Investor sentiment improved over the past week

New 90-day low: CN¥72.80

Third quarter earnings released

New 90-day low: CN¥80.03

New 90-day low: CN¥83.05

New 90-day low - CN¥85.65

First half earnings released

Guangzhou Wondfo Biotech Co.,Ltd to Report First Half, 2020 Results on Aug 28, 2020

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd